268545-13-7

Basic information

• Product Name: 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid
• Synonyms: (4R,7R)-Moxifloxacin;1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid;ent-Moxifloxacin;3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-Methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-;Moxifloxacin isoMer;1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride;Moxifloxacin (R,R)-Isomer;(4R,7R)-Moxifloxacin Hydrochloride 2
• CAS NO: 268545-13-7
• Molecular Formula: C21H24FN3O4
• Molecular Weight: 401
• Product Categories: Chiral Reagents;Heterocycles;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 268545-13-7.mol
• Article Data: 17

Chemical Properties

• Melting Point: 226-228°C (dec.)
• Boiling Point: 636.4±55.0 °C(Predicted)
• Appearance: /
• Density: 1.408
• Storage Temp.: -20?C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly), Water (Slightly)
• PKA: 6.43±0.50(Predicted)
• CAS DataBase Reference: 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid(268545-13-7)
• EPA Substance Registry System: 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid(268545-13-7)

Safety Data

• Hazardous Substances Data: 268545-13-7(Hazardous Substances Data)

Usage

Description

1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid is a complex organic compound with a unique molecular structure. It is characterized by its cyclopropyl, fluoro, and methoxy groups, as well as its octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl moiety. 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid exhibits a pale yellow solid appearance and has potential applications in various industries due to its chemical properties.

Uses

Used in Pharmaceutical Industry:
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid is used as an active pharmaceutical ingredient (API) for the development of new drugs. Its unique molecular structure and chemical properties make it a promising candidate for targeting specific biological pathways and treating various diseases.
Used in Antimicrobial Applications:
In the pharmaceutical industry, 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid is used as an antimicrobial agent. It is particularly effective against mycobacterial infections, such as tuberculosis, due to its ability to inhibit bacterial growth and proliferation.
Used in Cytotoxic Applications:
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid is also used in the development of cytotoxic drugs, which are designed to target and destroy cancer cells. Its potential to modulate oncological signaling pathways and exert inhibitory effects on tumor growth and progression makes it a valuable asset in the fight against cancer.
Used in Drug Delivery Systems:
To enhance the bioavailability and therapeutic outcomes of 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid, novel drug delivery systems have been developed. These systems, which may include organic and metallic nanoparticles, aim to improve the compound's delivery to target cells and tissues, ultimately enhancing its efficacy in treating various diseases.

Upstream product

• 112811-72-0 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid 
• 151213-40-0 (1S,6S)-2,8-diazabicyclo[4.3.0]nonane 
• 496919-99-4 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinoline-carboxylic acid O₃,O₄-bis(propyloxy-O)borate 
• 186826-86-8 moxifloxacin hydrochloride 
• 1028205-69-7 C₂₅H₃₃FN₄O₃ 
• 1028205-70-0 C₃₂H₃₇FN₄O₅ 
• 1028205-71-1 C₃₀H₄₁FN₄O₅ 
• 1028205-72-2 C₂₁H₂₅FN₄O₃ 
• 112811-70-8 ethyl 3-(cyclopropylamino)-2-(2,4,5-trifluoro-3-methoxybenzoyl)acrylate 
• 128740-14-7 8-benzyl-2,8-diazabicyclo[4.3.0]nonane 
• 151213-42-2 [R,R]-2,8-diazabicyclo[4.3.0]nonane 

Downstream Products

• 721970-35-0 methyl 1-cyclopropyl-6-fluoro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 721970-37-2 N-methylmoxifloxacin 
• 172426-88-9 7-amino-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxoquinoline-3-carboxylic acid 
• 721970-36-1 1-cyclopropyl-7-{(S,S)-2,8-diazabicyclo[4.3.0]non-8-yl}-6-fluoro-8-hydroxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid 
• 1029364-75-7 1-cyclopropyl-8-ethoxy-6-fluoro-7-((4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4 oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 925684-93-1 Benzyl 1-cyclopropyl-6-fluoro-1,4-dihydro-7-((4aS,7aS)-octahydropyrrolo[3,4-b]pyridin-6-yl)-8-methoxy-4-oxoquinoline-3-carboxylate 

Relevant articles and documents

Preparation method of moxifloxacin

The invention provides a preparation method of moxifloxacin, which comprises the following steps: taking 1-cyclopropyl-6, 7-difluoro-8-methoxy-4-oxo-1, 4-dihydro-3-quinolinecarboxylic acid and (S, S)-2, 8-diazabicyclo[4.3. 0] nonane as raw materials, in an organic solvent, in the presence of an acid-binding agent, and carrying out condensation reaction by taking the tri-coordinated boride cation-chloroaluminate ionic liquid as a catalyst to prepare moxifloxacin. The structural formula of the tri-coordinated boride cation-chloroaluminate ionic liquid is BX2L, X is a halogen atom, and L is selected from 4-picoline (4-pic), imidazole (mim) and dimethylacetamide (DMA) ligands. The preparation method of moxifloxacin has the advantages of simple reaction steps, high yield, high product purity, mild conditions and easiness in industrial production.

Nano-Fe3 O4@ZrO2-SO3 H as highly efficient recyclable catalyst for the green synthesis of fluoroquinolones

Nano-Fe3 O4 @ZrO2-SO3 H (n-FZSA), was utilized as a magnetic catalyst for the synthesis of various fluoroquinolone compounds. These compounds were prepared by the direct amination of 7-halo-6-fluoroquinolone-3-carboxylic acids with piperazine derivatives and (4aR,7aR)-octahydro-1H-pyrrolo[3,4-b] pyridine in water. The results showed that n-FZSA exhibited high catalytic activity towards the synthesis of fluoroquinolone derivatives, giving the desired products in high yields. Furthermore, the catalyst was recyclable and could be used at least seven times without any discernible loss in its catalytic activity. Overall, this new catalytic method for the synthesis of fluoroquinolone derivatives provides rapid access to the desired compounds in refluxing water following a simple work-up procedure, and avoids the use of organic solvents.

Fluorescence quenching study of moxifloxacin interaction with calf thymus DNA

Moxi oxacin (MOX) is a fourth-generation synthetic uoroquinolone antibacterial agent with many important therapeutic properties. Fluorescence quenching was used to study the interaction of MOX with calf thymus DNA (ct- DNA) in aqueous solution. The intercalative binding mode and a static quenching mechanism were conflrmed by the Stern-Volmer quenching rate constant (Kq) of 3.48 × 1011 M-1 s-1 at 298 K. The thermodynamic parameters (δH = -118.4 KJ mol-1 and δS = -299.4 J mol-1 K-1) were calculated at different temperatures, and they indicate that the main forces between MOX and ct-DNA are hydrogen bonding and Van der Waals force. We proved at the same time the presence of one single binding site on ct-DNA, and the binding constant is 1.28 × 105 M-1 at physiological pH. The results may provide a basis for further studies and clinical application of antibiotics drugs. Tubitak.